57 participants
PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2021-09-22
- Start Date:
- 2021-04-20
- Completion:
- 2022-12-30
Conditions
- Hepatocellular Carcinoma
Interventions
- DRUG
No Results Yet